MFDS approves new treatment for advanced colorectal cancer

Published: 2013-08-28 06:57:00

Updated: 2013-08-28 06:57:00

Bayer HealthCare Pharmaceuticals on Monday gained the green light from the Ministry of Food and Drug Safety (MFDS) on Stivarga (regorafenib) to treat patients with metastatic colorectal cancer (mCRC).

Stivarga is a multi-kinase inhibitor that blocks several enzymes that promote cancer growth. ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK